Skip to main content
Premium Trial:

Request an Annual Quote

Affy Names New Life Science President; 454 Wins World Economic Forum Award; Quantum Genomics Hires New R&D Head

NEW YORK (GenomeWeb News) — Affymetrix earlier this month disclosed that it had hired Kevin King as president of its life science business, and as executive vice president
King, 50 years old, previously worked at Thomson Corporation where he served as president and CEO of Thomson Healthcare from February 2005 to June 2006. 
From 1997 to 2004 King worked at GE Healthcare, most recently as vice president and general manager of the unit’s global clinical systems from June 2000 to November 2004.
According to a US Securities and Exchange Commission filing, King will receive an annual base salary of $450,000 and a $100,000 signing bonus. He will also be eligible to receive an annual bonus at a target level equal to 65 percent of his base salary for Affy’s bonus program in 2007.

454 Life Sciences was recently named one of thee World Economic Forum’s 47 Technology Pioneers for 2007. The winners were nominated by the world's “leading” venture capital and technology companies, according to the Forum. 
Winners “have been identified as developing and applying highly transformational and innovative technologies in the areas of energy, biotechnology and health, and information technology,” according to a statement.
“This year's class of companies has been selected not only because of the cutting-edge work undertaken by these organizations, but also because their work has potential long- term impact on business and society.”
Previous Technology Pioneers have included Autonomy, Cambridge Silicon Radio, Encore Software, Google, Millennium Pharmaceuticals, and Napster.
The 2007 winners are invited to attend the Annual Meeting of the World Economic Forum in Davos, Switzerland, on Jan. 24-28, 2007.

Quantum Genomics has appointed Fabrice Balavoine as head of research, where he will be responsible for managing partnerships with research labs and converting research results into the development phase.
He will also play a part in the chemical, production and monitoring aspects of products in preclinical development, according to Quantum.
Balavoine, 36, comes to Quantum from drug-discovery company Cerep, where he was head of drug development. He also worked as project leader at the Ecole Nationale Supérieure de Chimie in Paris, and at Harvard Medical School.